Frontotemporal lobar degeneration: Difference between revisions

Jump to navigation Jump to search
No edit summary
(/* DSM-V Diagnostic Criteria for Major Or Mild Frontotemporal Neurocognitive Disorder{{cite book | title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year ...)
Line 107: Line 107:
*1.Evidence of a causative frontotemporal neurocognitive disorder genetic mutation, from either family history or genetic testing.
*1.Evidence of a causative frontotemporal neurocognitive disorder genetic mutation, from either family history or genetic testing.


2.Evidence of disproportionate frontal and/or temporal lobe involvement from neuroimaging.
*2.Evidence of disproportionate frontal and/or temporal lobe involvement from neuro imaging.


'''''Possible frontotemporal neurocognitive disorder'''''is diagnosed if there is no evidence
'''''Possible frontotemporal neurocognitive disorder'''''is diagnosed if there is no evidence

Revision as of 19:40, 4 November 2014

Frontotemporal lobar degeneration
A human brain showing frontotemporal lobar degeneration causing frontotemporal dementia.
OMIM 600274
DiseasesDB 10034
MeSH D003704

WikiDoc Resources for Frontotemporal lobar degeneration

Articles

Most recent articles on Frontotemporal lobar degeneration

Most cited articles on Frontotemporal lobar degeneration

Review articles on Frontotemporal lobar degeneration

Articles on Frontotemporal lobar degeneration in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Frontotemporal lobar degeneration

Images of Frontotemporal lobar degeneration

Photos of Frontotemporal lobar degeneration

Podcasts & MP3s on Frontotemporal lobar degeneration

Videos on Frontotemporal lobar degeneration

Evidence Based Medicine

Cochrane Collaboration on Frontotemporal lobar degeneration

Bandolier on Frontotemporal lobar degeneration

TRIP on Frontotemporal lobar degeneration

Clinical Trials

Ongoing Trials on Frontotemporal lobar degeneration at Clinical Trials.gov

Trial results on Frontotemporal lobar degeneration

Clinical Trials on Frontotemporal lobar degeneration at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Frontotemporal lobar degeneration

NICE Guidance on Frontotemporal lobar degeneration

NHS PRODIGY Guidance

FDA on Frontotemporal lobar degeneration

CDC on Frontotemporal lobar degeneration

Books

Books on Frontotemporal lobar degeneration

News

Frontotemporal lobar degeneration in the news

Be alerted to news on Frontotemporal lobar degeneration

News trends on Frontotemporal lobar degeneration

Commentary

Blogs on Frontotemporal lobar degeneration

Definitions

Definitions of Frontotemporal lobar degeneration

Patient Resources / Community

Patient resources on Frontotemporal lobar degeneration

Discussion groups on Frontotemporal lobar degeneration

Patient Handouts on Frontotemporal lobar degeneration

Directions to Hospitals Treating Frontotemporal lobar degeneration

Risk calculators and risk factors for Frontotemporal lobar degeneration

Healthcare Provider Resources

Symptoms of Frontotemporal lobar degeneration

Causes & Risk Factors for Frontotemporal lobar degeneration

Diagnostic studies for Frontotemporal lobar degeneration

Treatment of Frontotemporal lobar degeneration

Continuing Medical Education (CME)

CME Programs on Frontotemporal lobar degeneration

International

Frontotemporal lobar degeneration en Espanol

Frontotemporal lobar degeneration en Francais

Business

Frontotemporal lobar degeneration in the Marketplace

Patents on Frontotemporal lobar degeneration

Experimental / Informatics

List of terms related to Frontotemporal lobar degeneration

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Synonyms and keywords: FTLD, frontotemporal lobar degeneration with tau inclusions, ftld with tau inclusions, frontotemporal dementia with parkinsonism, frontotemporal lobe dementia, fldem, ftdp17, multiple system tauopathy with presenile dementia, mstd, disinhibition-dementia-parkinsonism-amyotrophy complex, ddpac, frontotemporal dementia-amyotrophic lateral sclerosis, ftd-als pallidopontonigral degeneration, ppnd

Overview

Frontotemporal lobar degeneration (FTLD) is a pathologic process involving degeneration of gray matter in the frontal lobe and anterior portion of the temporal lobe of the cerebrum, with sparing of the parietal and occipital lobes.

Pathophysiology

The gross finding of frontotemporal lobar degeneration is likely produced by several etiologically distinct processes, with unique genetic and histopathological findings. Accordingly, there are a number of possible histopathological findings at post-mortem:

  • tau inclusions (either with Pick bodies or without)
  • ubiquitin positive (tau-negative) inclusions - in the majority of cases that have this type of pathology the ubiquitinated inclusions contain a protein called TDP-43. There are three subtypes of this type of pathology. Mackenzie et al (and subsequently Davidson et al) describe the following: type 1 with intranuclear inclusions; type 2 with neurites predominantly and type 3 with cytoplasmic inclusions predominantly. It should be noted that not all ubiquitin-positive, tau negative cases stain for TDP-43 e.g. the CHMP2B cases but also other cases.
  • Dementia lacking distinctive histology (DLDH) - A rare and controversial entity - new analyses have allowed many cases to be reclassified into one of the positively-defined subgroups.

Genetics

Many cases (possibly up to 50%) of FTLD are genetic rather than sporadic. Mutations in the Tau gene (on chromosome 17q21 - known as MAPT or Microtubule Associated Protein Tau) can cause FTLD and there are over 40 known mutations at present. A series of new mutations associated with FTLD has been recently described in the progranulin gene which is remarkably also on chromosome 17q21. Patients with progranulin mutations have type 1 TDP-43 positive, tau negative pathology at post-mortem. Progranulin is associated with tumorgenesis when overproduced, whereas the mutations seen in the progranulin gene associated with FTLD suggests a deficit in progranulin may be the problem. There are currently 2 other known genes that can cause FTLD: CHMP2B (on chromosome 3) which is associated with a behavioural syndrome (mainly in a large Jutland cohort); and VCP (valosin-containing protein, on chromosome 9) which is associated with the IBMPFD syndrome (inclusion body myopathy, Paget's disease and frontotemporal dementia). These 2 genes only account for a tiny proportion of cases. A locus on chromosome 9 is associated with FTD-MND (or FTD-ALS) i.e. frontotemporal dementia associated with motor neurone disease (or amyotrophic lateral sclerosis) - the hunt for this gene is currently the focus of a number of research labs around the world.

Differential Diagnosis Of Major or Mild Frontotemporal Neurocognitive Disorder

  • Other neurocognitive disorders
  • Other neurological conditions
  • Other mental disorders and medical conditions

Epidemiology and Demographics Of Major or Mild Frontotemporal Neurocognitive Disorder

Prevalence

The prevalence of major or mild frontotemporal neurocognitive disorder is 2,000-10,000 per 100,000 (2%-10%) of the overall population.[1]

Age

In the over 65 age group, FTLD is probably the fourth most common cause of dementia after Alzheimer's disease, Dementia with Lewy bodies and vascular dementia. In the below 65 age group, it is the second most common cause after Alzheimer's disease. The process of FTLD is thought to be the main cause of three clinical syndromes: frontotemporal dementia, semantic dementia, and progressive nonfluent aphasia.

Risk Factors Of Major or Mild Frontotemporal Neurocognitive Disorder

Diagnosis

Symptoms

Physical Examination

Neuro

DSM-V Diagnostic Criteria for Major Or Mild Frontotemporal Neurocognitive Disorder[1]

  • A.The criteria are met for major or mild neurocognitive disorder.

AND

  • B.The disturbance has insidious onset and gradual progression.

AND

  • C.Either (1) or (2);
  • 1.Behavioral variant;
  • a.Three or more of the following behavioral symptoms:
  • i.Behavioral disinhibition.
  • ii.Apathy or inertia.
  • iii.Loss of sympathy or empathy.
  • iv.Perseverative, stereotyped or compulsive/ritualistic behavior.
  • v.Hyperorality and dietary changes.
  • b.Prominent decline in social cognition and/or executive abilities.
  • 2.Language variant:
  • a.Prominent decline in language ability, in the form of speech production, word finding, object naming, grammar, or word comprehension.

AND

  • D.Relative sparing of learning and memory and perceptual-motor function.

AND

  • E.The disturbance is not better explained by cerebrovascular disease, another neurodegenerative disease, the effects of a substance, or another mental, neurological, or systemic disorder.

Probable frontotemporal neurocognitive disorderis diagnosed if either of the following is present; otherwise, possible frontotemporal neurocognitive disorder should be diagnosed:

  • 1.Evidence of a causative frontotemporal neurocognitive disorder genetic mutation, from either family history or genetic testing.
  • 2.Evidence of disproportionate frontal and/or temporal lobe involvement from neuro imaging.

Possible frontotemporal neurocognitive disorderis diagnosed if there is no evidence of a genetic mutation, and neuro imaging has not been performed.

References

  1. 1.0 1.1 1.2 1.3 Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.

See also

sv:Frontallobsdemens


Template:WikiDoc Sources